de.mpg.escidoc.pubman.appbase.FacesBean
Deutsch
 
Hilfe Wegweiser Impressum Kontakt Einloggen
  DetailsucheBrowse

Datensatz

DATENSATZ AKTIONENEXPORT

Freigegeben

Vortrag

A generic purification scheme for the production of human influenza vaccines derived from serum-free mammalian cell culture

MPG-Autoren
http://pubman.mpdl.mpg.de/cone/persons/resource/persons86343

Kalbfuss,  B.
Bioprocess Engineering, Max Planck Institute for Dynamics of Complex Technical Systems, Max Planck Society;

http://pubman.mpdl.mpg.de/cone/persons/resource/persons86517

Wolff,  M. W.
Bioprocess Engineering, Max Planck Institute for Dynamics of Complex Technical Systems, Max Planck Society;
Otto-von-Guericke-Universität Magdeburg, External Organizations;

http://pubman.mpdl.mpg.de/cone/persons/resource/persons86303

Genzel,  Y.
Bioprocess Engineering, Max Planck Institute for Dynamics of Complex Technical Systems, Max Planck Society;

http://pubman.mpdl.mpg.de/cone/persons/resource/persons86531

Zimmermann,  A.
Bioprocess Engineering, Max Planck Institute for Dynamics of Complex Technical Systems, Max Planck Society;

http://pubman.mpdl.mpg.de/cone/persons/resource/persons86448

Reichl,  U.
Otto-von-Guericke-Universität Magdeburg;
Bioprocess Engineering, Max Planck Institute for Dynamics of Complex Technical Systems, Max Planck Society;

Externe Ressourcen
Es sind keine Externen Ressourcen verfügbar
Volltexte (frei zugänglich)
Es sind keine frei zugänglichen Volltexte verfügbar
Ergänzendes Material (frei zugänglich)
Es sind keine frei zugänglichen Ergänzenden Materialien verfügbar
Zitation

Kalbfuss, B., Wolff, M. W., Genzel, Y., Zimmermann, A., Best, C., Morenweiser, R., et al. (2006). A generic purification scheme for the production of human influenza vaccines derived from serum-free mammalian cell culture. Talk presented at Vaccine Technology. Puerto Vallarta, Mexico. 2006-06-25 - 2006-06-30.


Zitierlink: http://hdl.handle.net/11858/00-001M-0000-0013-9A27-2
Zusammenfassung
Epidemic spreading of avian influenza has once again stressed the importance of vaccination as the principal means of prophylaxis. The production of influenza vaccines in mammalian cell culture has been suggested before. Here, we present a downstream processing scheme for the production of an inactivated whole-virion human influenza vaccine from human influenza A virus propagated in serum-free mammalian cell culture. Human influenza virus A/PR/8/34 (H1N1) was replicated in adherent Madin-Darby canine kidney cells (ECACC #841211903) grown in roller bottles using serum-free cell culture medium. After pooling of the supernatants cell debris was removed by a combination of depth and membrane filters with an intermediate inactivation step using β-propiolactone. The virus was then concentrated 20-fold by cross-flow ultrafiltration resulting in a first reduction of impurities. Levels of host cell protein and genomic DNA were further depleted by two subsequent chromatography steps: size-exclusion and anion-exchange chromatography. Yields of the depth and membrane filtration were consistently high with average values of 85% and 93%, respectively. In contrast, the yield of the concentration step was very sensitive to the filtration flux. A high flux led to membrane fouling and partial loss of the product. Limiting the flux to 28 l m-2 h-1, however, resulted in an average yield of 97%. The average yield of the size-exclusion chromatography was 85%. In order to maximize productivity, the injection volume and the fractionation were optimized in a modeling study. Anion-exchange chromatography was run in negative mode (virus in flowthrough). The optimal ionic strength to separate virus from DNA was determined in microtiter plate experiments. The product yield depended on the amount of virus loaded. Satisfactory yields of 82% were obtained for viral loads > 160 kHAU per ml of resin. An overall yield of 53% based on hemagglutination activity could be achieved. The amount of total protein (including the virus) and host cell DNA could be reduced to 3.5% and 0.19%, respectively. The protein purity of the final product was at least 94%. First estimations of the dose volume based on total protein measurements and hemagglutination activity (assuming 15 µg of HA antigen per dose) indicated that a DNA